- Home
- LBRDA vs KNSA Comparison
LBRDA vs KNSA Comparison
Compare LBRDA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRDA | KNSA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LBRDA | KNSA |
|---|---|---|
| Price | $36.83 | $78.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $60.86 |
| AVG Volume (30 Days) | 252.6K | ★ 467.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.91 | ★ 225.00 |
| EPS | ★ 4.55 | 0.27 |
| Revenue | $22,256,000.00 | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $109.28 | $17.87 |
| P/E Ratio | ★ $7.91 | $295.56 |
| Revenue Growth | ★ 70.00 | 60.09 |
| 52 Week Low | $26.14 | $33.54 |
| 52 Week High | $65.40 | $82.94 |
Technical Indicators
Market Signals| Indicator | LBRDA | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 59.00 |
| Support Level | $29.39 | $44.95 |
| Resistance Level | $37.32 | $82.25 |
| Average True Range (ATR) | 1.58 | 2.23 |
| MACD | -0.03 | -0.56 |
| Stochastic Oscillator | 67.35 | 56.73 |
Price Performance
Historical ComparisonAbout LBRDA Liberty Broadband Corporation
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.